Neurofibromatosis - Diagnostic Assessment by Sónia Costa et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
11 
Neurofibromatosis – Diagnostic Assessment 
Sónia Costa, Raquel Tojal and Ana Valverde 
Neurology Department, Hospital Professor Dr. Fernando Fonseca EPE,  
Amadora,  
Portugal 
1. Introduction 
Descriptions of individuals supposed to have neurofibromatosis have been discovered in 
manuscripts dating from 1000 AD (Zanca, 1980). However, it was not until 1881 that Von 
Recklinghausen coined the term ‘‘neurofibroma’’ when he observed that this benign tumour 
arose from the peripheral nerve sheath. His colleagues honored his contribution by naming 
the condition Von Recklinghausen’s disease. However, the different forms of 
neurofibromatosis were not separated and delineated until the latter part of the twentieth 
century (Ferner et al., 2007a). Neurofibromatosis is one of the called “neurocutaneous 
disorders” or “phakomatoses”, genetic diseases that involve both skin and the nervous 
system. They share some features: hereditary transmission, involvement of organs of 
ectodermal origin and a tendency to develop certain types of central and peripheral nervous 
system tumours. Advances in clinical genetics allowed to separate neurofibromatosis in two 
diseases, each caused by a different gene, although recognition still requires an appreciation 
of the cutaneous and systemic symptoms. (Ferner 2007a, 2010) 
2. Clinical manifestations and diagnostic criteria 
2.1 Neurofibromatosis 1 
Neurofibromatosis 1 (NF1) is an autosomal dominant disorder with an incidence of 1 in 
3,500 live births. Half of all cases are spontaneous mutations. The gene was cloned on 
chromossome 17q11.2 in 1990. Neurofibrin, the protein product, is widely expressed with 
high levels in the nervous system. It acts as a tumour suppressor which explains why 
NF1 patients are prone to developing benign and malignant tumours (Ferner, 2010). 
Although recent advances in genetic testing may permit the laboratory diagnosis in as 
many as 95%, for the majority of patients the diagnosis is made on the basis of clinical 
manifestations. Diagnosis requires the presence of 2 or more major criteria: 6 or more café 
au lait spots, axillary or inguinal freckling, 2 or more cutaneous neurofibromas, 1 
plexiform neurofibroma, characteristic bony lesions (pseudarthrosis, sphenoid wing 
hypoplasia), an optic glioma, 2 or more iris Lisch nodules, or a first-degree relative with 
NF1 (Table 1). Diagnosis can be made at birth in some cases, whereas others must be 
monitored for a few years for the presence of additional criteria (Ferner et al., 2007a, b, 
2010; Tonsgard, 2006).  
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6 or more café au lait spots (>0,5 cm in prepubertal children, >1,5 cm in postpubertal individuals) 
Axillary or inguinal freckling 
2 or more cutaneous neurofibromas 
1 plexiform neurofibroma 
2 or more iris Lisch nodules 
An optic glioma 
Characteristic bony lesions (pseudarthrosis, sphenoid wing hypoplasia) 
A first-degree relative with NF1 
Table 1. Diagnostic Criteria for NF1 
2.1.1 Cutaneous manifestations 
Café au lait spots are generally the heralding feature of NF1. Café au lait spots are 
hyperpigmented flat spots that are oval or rounded with fairly smooth borders (Fig 1a). 
They are present at birth in many individuals and increase in size and number over the first 
5 to 7 years of life. Most, but not all patients with NF1, have café au lait spots (Tonsgard, 
2006).  
Freckling is reported in children of about 3 years of age in the axillae, groins, around the 
neck, on the eyelids, and under the breasts. However it may not appear until 5 to 7 years of 
age (Tonsgard, 2006).  
Cutaneous angiomas and hypopigmented maculaes are described, and xanthogranulomas 
(Fig1b) can appear fleetingly during childhood as orange papules. Cutaneous or dermal 
neurofibromas are tumors of the nerve sheath comprised of Schwann cells, fibroblasts, 
perineural cells, mast cells, axons, and blood vessels (Lott & Richardson, 1981). They may 
become visible in childhood but more commonly develop in adolescence or adulthood (Fig 
1a). They may be purplish depressions in the skin or pedunculated lesions. Plexiform 
neurofibromas are histologically similar to cutaneous neurofibromas but have more 
extracellular matrix (Fig 1c). Often, they arise from the dorsal spinal roots, nerve plexus, 
large nerve trunks, or sympathetic chains. Plexiform tumours may be discrete, 
homogeneous, well circumscribed or diffuse, heterogeneous, and infiltrative. They may 
involve superficial skin or be entirely internal. They occur in at least 50% of patients and are 
probably present at birth. Many are asymptomatic (Tonsgard et al., 1998).  
 
Fig. 1. A – Café au lait (black arrows) and pedunculated cutaneous neurofibromas (white 
arrow) B – Xanthogranuloma. C –Plexiform neurofibroma (blue arrow) 
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Individuals with NF1 harbor a 7–13% lifetime risk of developing malignant peripheral nerve 
sheath tumors (MPNST), which usually arises in a pre-existing plexiform or a focal 
subcutaneous neurofibroma. Cutaneous neurofibromas do not become malignant. MPNSTs 
metastasize widely and often presage a poor outcome. Vigilant monitoring is recommended 
for patients with a past history of malignancy or radiotherapy, a family history of MPNST, 
internal neurofibromas, lesions in the brachial or lumbosacral plexus, or neurofibromatous 
neuropathy. Individuals with neurofibromatous neuropathy have a mild axonal sensory 
and motor neuropathy with diffuse neurofibromatous change in the nerves. (Ferner, 2007a) 
Diagnosis of MPNST is problematic within the context of NF1 because the emergence of a 
lump is not unusual. The clinical symptoms of malignancy are intertwined with the 
symptoms of benign tumours. Plexiform neurofibromas that are associated with persistent 
or nocturnal pain, rapid increase in size, change in texture, or new or unexplained 
neurological deficit require urgent assessment at a specialist unit. Targeted biopsy with 18-
fluorodeoxyglucose (FDG) PET is the best method for diagnosis (Ferner et al., 2000).  
2.1.2 Ocular/orbit manifestations 
NF1 may affect the iris, retina, optic nerve, and the bony and soft tissue of the orbit. Lisch 
nodules are proliferations of melanocytes and fibroblasts that appear as reddish brown 
spots in the iris of blue- or green-eyed people and hypopigmented spots in brown eyed 
people. They are commonly found in the lower pole of the iris and have no effect on vision 
(Fig 2). Onset is usually in the teenage years. They are present in 90% of adults. Retinal 
hamartomas occur in a small percentage of patients. Optic gliomas (visual pathway tumors) 
are grade I pilocytic astrocytomas found in 15% of patients. They produce thickening of the 
optic nerve (Fig 3). Frequently bilateral and often involving the chiasm, they may extend to 
the optic tracts or inferiorly into the hypothalamus. They may present as decreased color 
vision or an afferent papillary defect and later with pallor of the optic disc or a decrease in 
visual acuity between 15 months to 7 years of age. Plexiform neurofibromas of the orbit are 
frequently found in patients with optic gliomas (Liternick et al., 1989; Tonsgard, 2006; 
Ferner, 2010). 
 
Fig. 2. Lisch Nodules  
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2.1.3 Bone abnormalities 
Orthopedic problems arise in patients with NF1 from inherent abnormalities in the 
maintenance of bone structure and from reduction in bone mineral density. Individuals with 
NF1 have an increased risk of developing osteoporosis and osteopenia, which 
predominantly affect the load-bearing parts of the body (Crawford & Bagamery, 1986; 
Ferner, 2007). 
Complications can also result from bony overgrowth or destruction caused by underlying 
plexiform neurofibromas. Bony dysplasia, bony erosion, demineralization, non ossifying 
fibromas, and scoliosis are all features of NF1. Dysplastic bony lesions include splayed ribs, 
vertebral anomalies, hypoplasia of the sphenoid or mandible, and pseudarthrosis. 
Pseudarthrosis most commonly involves the tibia and presents in early infancy with bowing 
of the affected limb followed by pathological fracture and impaired healing. The disorder 
represents thinning of the long bone cortex and the development of a false joint in a long 
bone (Crawford & Bagamery, 1986; Ferner, 2007). 
Scoliosis affects 10% of those with NF1, most commonly involves the lower cervical and 
upper thoracic spine, and can be either idiopathic or dystrophic. The latter does not usually 
develop before 6 years of age and is rare after the first decade of life. Typically, there is a 
short curve with severe apical rotation, distortion of the vertebral bodies and ribs, and rapid 
disease progression (Crawford & Bagamery, 1986; Ferner, 2007). 
2.1.4 Cardiovascular problems 
An international database review identified cardiovascular malformations in 2% of patients 
with NF1 and most individuals had pulmonary stenosis. Hypertension occurs with 
increased frequency and is associated with premature death in adults with NF1. High blood 
pressure can be idiopathic or the result from dysplastic renal artery stenosis or 
pheochromocytoma. Dysplasia of blood vessels is usually multifocal and bilateral. The most 
common sites are kidney and brain (Lin et al., 2000; Ferner, 2007). 
2.1.5 Neurological manifestations 
Neurological complications affect both the peripheral and central nervous system, 
accounting for significant morbidity and mortality in NF1.  
As already described, cutaneous neurofibromas are tumours of peripheral nerves, and 
plexiform neurofibromas can involve large nerves, plexus, spinal roots, sympathetic 
nerves, or small peripheral nerve fibers. Involvement of large nerves such as the sciatic 
may be asymptomatic or suggested only by hypertrophy of the affected extremity. When 
the sacral plexus is involved, there can be massive proliferation of tumor with infiltration 
of the bladder and compression of the ureters, rectum, and uterus. Plexiform tumours of 
the spinal roots may cause pain and erosion of the neural foramen or cord compression. 
High cervical nerve root neurofibromas are prone to compress the cord but the 
neurological deficit is frequently mild in comparison with the neuroimaging appearances. 
Involvement of the lumbar roots causes back pain that is aggravated by exertion 
(Tonsgard, 2006; Ferner, 2007). 
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Neurofibromatous neuropathy affects at least 1% of NF1 adults. They present with mild 
distal sensory and motor symptoms. Thickened peripheral nerves are infiltrated with 
neurofibromatous tissue. Although NF1 neurofibromatous neuropathy is not progressive, 
affected individuals require assiduous monitoring because they are at risk of developing 
malignant peripheral nerve sheath tumors (Ferner, 2010). 
Cognitive disability is the commonest neurological symptom in children with NF1 and does 
not improve in adulthood. Characteristically, the intelligent quotient (IQ) is in the low-
average range but mental retardation (IQ<70) is uncommon. Children with NF1 have 
specific learning difficulties that include visual spatial problems, impaired visual motor 
integration with abnormal ocular saccades, language deficits, and disorder of executive 
function. Problems that are typically associated with the NF1 phenotype include attention 
deficit hyperactivity disorder, which responds to methylphenidate medication, and poor 
socialization (Hyman et al., 2005). 
Chiari 1 malformation and aqueduct stenosis due to subependymal glial cell proliferation 
are encountered in 1.5 % of NF1 patients (Valverde et al., 2007). Hydrocephalus is an 
uncommon complication. Sphenoid wing dysplasia is noticeable as pulsating exophthalmos 
without visual compromise; the absent sphenoid wing allows the temporal lobe to prolapse 
forwards into the orbit but surgical correction is not usually undertaken (Ferner et al., 
2007a). 
Epilepsy is diagnosed in about 6% of NF1 patients, it is frequently mild and it tends to start 
between childhood and middle age. There are several underlying causes, comprising brain 
trauma, infection unrelated to NF1, mesial temporal sclerosis, NF1 related gliomas and 
anecdotal reports of dysembryoblastic neuroepithelial tumours. All seizure types occur but 
complex partial seizures predominate. 
Cerebrovascular problems have been reported in 2·5% of children with NF1 and include 
stenosis or occlusion of the internal carotid and cerebral arteries, aneurysms, and 
Moyamoya disease (Rosser et al., 2005). 
Headaches occur in 20% of patients; most of these are consistent with migraine and respond 
well to prophylactic medications (Tonsgard, 2006).  
Gliomas occur in all parts of the brain but have a predilection for the optic pathways, 
brainstem, and cerebellum. They are usually indolent pilocytic astrocytomas, but those that 
arise outside the optic pathways, which are symptomatic lesions or that release in 
adulthood, are more aggressive and are associated with a worse prognosis. About 15% of 
NF1 children have optic pathway gliomas but only 5% develop symptoms or signs (figure 
3). They usually present before the age of 6 years and can cause impaired visual acuity and 
color vision, squint, proptosis, afferent pupillary defect, optic atrophy, visual field defects 
and precocious puberty. Adult onset or tumor progression, are unusual and visual 
screening is not required in adulthood. Young children rarely complain of visual loss and 
the best method of diagnosis is regular visual screening, at least until the age of 7 years. 
Grade III and IV astrocytomas occur in NF1 and require aggressive treatment. They are 
invariably symptomatic. The best outcome implies complete surgical removal coupled with 
chemotherapy. The outcome for malignant brain tumors in patients with NF1 is generally 
better than in not affected individuals (Liternick et al., 1989; Tonsgard, 2006; Ferner, 2010). 
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Fig. 3. Optic pathway gliomas involving both optic nerves (black arrows) 
Primary progressive multiple sclerosis occurs with increased frequency in NF1 and relapsing 
remitting disease has also been reported. Although NF1 is a tumour suppressor condition, 
immunosuppressant therapy is not contraindicated and so far, there is no evidence of an 
increase in malignancy in NF1 patients with multiple sclerosis (Ferner, 2007b). 
2.2 Neurofibromatosis 2 
Neurofibromatosis type 2 (NF2), primarily known as acoustic neurofibromatosis or central 
neurofibromatosis is an autossomal dominant disorder caused by mutations on the NF2 
gene, a tumour suppressor gene located on chromosome 22q12 that encodes a protein 
termed Merlin/Schwannomin, causing diminished or loss of function of these protein 
(Asthagiri et al, 2009; Ferner, 2007b; Gareth & Evans, 2009). It is less common than NF1, 
accounts for 5 to 10% of all cases of Neurofibromatosis and has an incidence of 1 in 25,000 
livebirths and a prevalence of 1 in 60,000 (Asthagiri et al, 2009; Ferner, 2007b; Pérez-Grau et 
al, 2010). The average age of onset is 22 years of age (Asthagiri et al, 2009; Ferner, 2007b) 
(Gareth & Evans, 2009). There is a risk of 50% of an affected individual to transmit the 
mutation to their offspring and the penetrance will be complete at 60 years of age, however 
there is a high phenotypic variability between individuals, even within the same 
family(Asthagiri et al, 2009; Gareth & Evans, 2009). About one third of NF2 patients are 
mosaic, which means that the mutation took place after conception and that only certain 
cells of the body will be affected and these patients will have a milder form of the disease 
(Ferner, 2007b; Gareth & Evans, 2009; Pérez-Grau et al, 2010). 
The characteristic feature is bilateral vestibular schwannomas (on cranial nerve VIII) that 
occur in 90-95% of patients. They present most commonly with progressive sensorineural 
hearing loss as the first sign, frequently unilateral at onset (Ferner, 2010; Gareth & Evans, 
2009; Pérez-Grau et al, 2010). Since schwannomas usually do not develop before 
adolescence, in children the first manifestation, contrary to what occurs in adulthood, can be 
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cranial, orbital or spinal meningioma, spinal or cutaneous schwannoma, mononeuropathy, 
focal amyotrophy or cataracts (Ferner, 2007b, 2010; Gareth & Evans, 2009; Pérez-Grau et al, 
2010). Contrarily to tumours in NF1, schwannomas are benign tumours and the morbidity 
and early mortality rates are due to the multiple tumours in central and peripheral nervous 
system (Asthagiri et al, 2009; Ferner, 2007a; Pérez-Grau et al, 2010) 
The efficiency of the set of existing criteria was compared in a study selecting 163 people 
from NF2 registry without bilateral vestibular schwannomas. (Baser et al., 1996) They 
evaluated the criteria for “definite NF2” and “probable NF2” at two points: initial assessment 
and the most recent clinical evaluation. (Baser et al., 1996) For both points, the Manchester 
criteria and the NNF (National Neurofibromatosis Foundation) criteria identified a higher 
proportion of people than with the NIH (National Institute of Health) criteria. The Manchester 
criteria identified an even higher number of people because they are based on the number of 
disease features of any types and a determined age is not necessary for diagnosis, contrary to 
NNFF which requires a certain number of different feature types and the existence of 
unilateral vestibular schwannomas with less than 30 years of age. The 1987 and the 1991 NIH 
Criteria each require a positive family history for the diagnosis of NF2 in people who do not 
have bilateral vestibular schwannomas, therefore, the proportion of these people identified 
with “possible NF2” is low and even lower with “definite NF2”. (Baser et al., 1996) For people 
who do not have a family history of NF2 or bilateral vestibular schwannomas, a diagnosis can 
be made based on the Manchester and the NNFF criteria. (Baser et al., 1996) The Manchester 
criteria are more sensitive for identifying mosaics than all the other criteria. They considered 
that a new set of criteria should be created including the evidence of mononeuropathy (foot 
drop, wrist drop, facial palsy, or III nerve palsy) and the results of genetic testing. 
2.2.1 Cutaneous manifestations 
Three types of cutaneous tumours, all histologically schwannomas, are identified: cutaneous 
plaque-like lesions (raised, hyperpigmented and hairy), subcutaneous tumours (fusiform 
swelling) and intradermal tumours. (Asthagiri et al, 2009; Ferner, 2007b). These occur in 
about 70% of NF2 patients, though less prominent than in NF1 patients. (Gareth & Evans, 
2009; Pérez-Grau et al, 2010)  
 
Fig. 4. Cutaneous schwannoma 
Generally these tumours grow on or around a peripheral nerve (more frequently sensory 
nerves) and subcutaneous tumours usually cause pain and are sensitive to pressure. 
(McClatchey, 2007; Pérez-Grau et al, 2010) Rarely a cutaneous neurofibroma may appear or 
a dermal tumour may be confused with a neurofibroma. (Asthagiri et al, 2009; Ferner, 2007b; 
Gareth & Evans, 2009; McClatchey, 2007) 
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Café au lait patches are reported in almost 40% of patients with NF2, being more common 
than in the general population, but less numerous than in people with NF1 and generally 
they are singular and inconspicuous. (Asthagiri et al, 2009; Ferner, 2010) 
2.2.2 Neurological manifestations 
Although schwannomas on cranial nerve VIII are the cardinal feature of NF2, they can also 
grow on other cranial nerves (CN). The next most affected CN are III (oculomotor), V 
(trigeminal) and VII (facial), but they can affect IX-XII also (Ferner, 2010; Gutmann et al, 
1997). When tumours arise in III and V CN, they are usually asymptomatic, opposite to 
tumours of the lower cranial nerves, mostly symptomatic (Asthagiri et al, 2009). The initial 
symptom associated with vestibular schwannomas usually is progressive sensorineural 
hearing loss, which can be preceded or accompanied by tinnitus (Ferner, 2010; Gareth & 
Evans, 2009). Other symptoms associated are: vertigo, gait instability, facial weakness, 
twitching, sensory deficit and headache (Ferner, 2010; Pérez-Grau et al, 2010). The growth 
rates of vestibular schwannomas are variable, but higher in patient under 30 years of age. 
 
Fig. 5. Vestibular schwannoma (red arrows) 
Meningiomas are the second most frequent tumour in NF2 patients. They are generally 
multiple, can occur in brain or spine, and the symptoms vary according to the location 
(Goutagny & Kalamarides, 2010). Cranial meningiomas have a high rate of neurological 
problems and mortality (Asthagiri et al, 2009; Ferner, 2010). Optic meningiomas may cause 
vision loss due to compression of the optic nerve, especially in children (Bosch et al, 2006).  
Spinal schwannomas can occur and are regularly multiple (Ferner, 2010). These tumours 
and optic meningiomas can be found in about 90% of patients with NF2 (Ferner, 2010). For 
20-30% of NF2 patients the initial symptoms have their origin in intracranial meningiomas, 
spinal or cutaneous tumours (Gareth & Evans, 2009). 
Ependymomas (low-grade CNS malignancies) can be present, mostly in the brainstem 
and upper cervical cord and may be associated with a syrinx (fluid-filled cavity within 
spinal cord), with symptoms that could appear throughout life (Aguilera, 2011; Ferner, 
2010; Gareth & Evans, 2009). For spinal cord ependymomas, the intramedullary lesions 
may present themselves as back pain, weakness or sensory disturbances (Asthagiri et al, 
2009). 
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Fig. 6. Cranial meningiomas in NF2 patients 
Also associated to NF2 is an axonal peripheral neuropathy (Asthagiri et al, 2009; Ferner, 
2010). The majority of the cases are associated to tumours within or compressing the nerve, 
but in others the mechanisms are not yet fully understood as there is no evidence of a 
tumour and are probably related with compression from multiple Schwann cell tumourlets. 
(Asthagiri et al, 2009; Ferner, 2010). In children a clinical presentation with mononeuropathy 
(in particular facial nerve palsy) before the appearance of vestibular schwannomas is 
common, but also common is a polio-like illness (Ferner, 2007; Gareth & Evans, 2009). In 
both presentations full recovery is unusual. (Ferner, 2007a; Gareth & Evans, 2009).  
2.2.3 Ocular manifestations 
Usually lens changes appear in infancy or childhood (earlier than vestibular schwannomas) 
and most commonly include juvenile posterior subcapsular cataracts, cortical wedge 
cataracts and mixed cataracts and all can reduce visual acuity. (Gareth & Evans, 2009) They 
should be considered as specific of NF2 only in people younger than 50 years of age. They 
are present in about 60-80% of NF2 patients (Asthagiri et al, 2009; Gareth & Evans, 2009). 
Other manifestations are epiretinal membranes and retinal hamartomas. The first, opposite 
to the second, don’t usually affect visual acuity even in patients with severe disease, and 
may be present in more than a third of patients with NF2 (Asthagiri et al, 2009; Pérez-Grau 
et al, 2010). 
The onset at a young age of ophthalmologic symptoms is a risk factor for marked disease 
progression. (Bosch et al, 2006) Therefore people at risk of developing NF2 should be 
screened for these abnormalities in infancy (Gareth & Evans, 2009; Baser, 1996). 
Regarding diagnostic criteria, the National Institute of Health (NIH) Consensus Panel 
established in 1987 clinical guidelines for the diagnosis of Neurofibromatosis type 2, which 
were revised in 1991. However, these criteria were considered too rigid and leading to 
exclusion of patients that should be screened for NF2. Therefore, in 1997, a consensus review 
of published data was proposed by researchers in the neurofibromatosis field by the 
National Neurofibromatosis Foundation (NNF) (Gutmann et al., 1997; McClatchey, 2007). In 
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order to promote higher specificity and sensitivity, in 2002 new diagnostic criteria were 
established, based on a comparison of this four different sets of criteria for NF2 (Table 2) 
(Baser et al., 1996; Ferner, 2007a). 
1987 NIH criteria
A. Bilateral vestibular schwannomas 
B. First-degree family relative with NF2 and unilateral vestibular schwannoma or any two 
of: meningioma, schwannoma, glioma, neurofibroma, juvenile posterior subcapsular 
lenticular opacity 
1991 NIH criteria
A. Bilateral vestibular schwannomas 
B. First-degree family relative with NF2 and unilateral vestibular schwannoma or any one 
of: meningioma, schwannoma, glioma, neurofibroma, juvenile posterior subcapsular lens 
opacity 
Manchester criteria
A. Bilateral vestibular schwannomas 
B. First-degree family relative with NF2 and unilateral vestibular schwannoma or any two 
of: meningioma, schwannoma, glioma, neurofibroma, posterior subcapsular lenticular 
opacities 
C. Unilateral vestibular schwannoma and any two of: meningioma, schwannoma, glioma, 
neurofibroma, posterior subcapsular lenticular opacities 
D. Multiple meningiomas (two or more) and unilateral vestibular schwannoma or any two 
of: schwannoma, glioma, neurofibroma, cataract 
NNF criteria 
A. Confirmed or definite NF2 
1. Bilateral vestibular schwannomas 
2. First-degree family relative with NF2 and unilateral vestibular schwannoma at less than 
30 y of age or any two of: meningioma, schwannoma, glioma, juvenile lens opacity 
(posterior subcapsular cataract or cortical cataract) 
B. Presumptive or probable NF2 
1. Unilateral vestibular schwannoma at less than 30 y of age and at least one of: 
meningioma, schwannoma, glioma, juvenile lens opacity (posterior subcapsular cataract 
or cortical cataract) 
2. Multiple meningiomas (two or more) and unilateral vestibular schwannoma at less than 
30 y of age or at least one of: schwannoma, glioma, juvenile lens opacity (posterior 
subcapsular cataract or cortical cataract) 
Table 2. Clinical diagnostic criteria for NF2 (Baser ME, 2002) 
3. Differential diagnosis  
The differential diagnoses of NF1 includes other forms of neurofibromatosis, conditions 
with café au lait patches or with pigment changes confused with café au lait patches. 
Likewise, tumors or localized body overgrowth can be mistaken for neurofibromas (table 3). 
It should be emphasized that one or two café au lait patches occur in 10% of the general 
population. Children with 3–5 café au lait patches but no other signs of NF1 should be 
followed up in a specialist neurofibromatosis clinic as they might have mosaic NF1 or NF2 
(Ferner., 2007b).  
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Mosaic NF1 occurs as a result of a somatic mutation in the NF1 gene. The body’s proportion 
affected depends on mutation’s timing in embryonic development. The importance of 
making the diagnosis is that NF1 complications are relatively infrequent in segmental NF1 
and there is a much lower risk of recurrence in offspring. Homozygotes for one of the genes 
causing hereditary non-polyposis cancer of the colon have café au lait patches and an 
affected first degree relative. However, the affected relative is a sibling and the parents are 
normal (Ruggierei & Huson, 2001).  
The only subtype of NF1 that is distinct and has a uniform phenotype in families is Watson 
syndrome. It is characterized by pulmonary stenosis, cognitive impairment, café au lait 
patches and few, if any, cutaneous neurofibromas (Korf & Huson, 2006).  
There is no clear evidence that neurofibromatosis–Noonan syndrome exists as a distinct 
phenotype with features of both syndromes. It is likely that some individuals with NF1 
simply have facial features similar to those of Noonan syndrome and these characteristics 
are not consistent within families. Molecular studies indicate that neurofibromatosis–
Noonan syndrome is caused by mutations of the NF1 gene, some of which have been 
identified in patients with classical NF1 (De Luca et al., 2002). 
Other forms of neurofibromatosis:
Segmental/mosaic NF1 
Watson syndrome 
Autossomal dominant multiple café au lait alone 
Neurofibromatosis 2 
Schwannomatosis
Other conditions with café au lait patches:
McCune-Albright syndrome 
DNA repair syndromes 
Homozigoty for one of the genes causing hereditary non-polyposis cancer of the colon 
Conditions with pigmented macules confused with NF1:
LEOPARD syndrome 
Neurocutaneous melanosis 
Peutz-Jehers syndrome 
Piebaldism 
Localized overgrowth syndrome:
Klippel-Trenauny-Weber syndrome 
Proteus syndrome
Conditions causing tumors confused with neurofibromas:
Lipomatosis 
Banaya-Riley-Ruvalcuba syndrome 
Fibromatoses 
Multiple endocrine neoplasia type 2B
Table 3. Differential diagnosis of neurofibromatosis 1 
NF2 is clinically and genetically distinct from NF1, and is characterized by bilateral 
vestibular schwannomas. Affected individuals also develop schwannomas on other cranial, 
spinal, peripheral and cutaneous nerves. Café au lait patches are less numerous than in NF1, 
and the skin lesions are predominantly schwannomas. Central nervous system 
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meningiomas and gliomas are observed, and slit lamp examination reveals juvenile 
subcapsular lens opacities in the majority of patients. Subcutaneous, peripheral nerve and 
spinal schwannomas lead to schwannomatosis without vestibular schwannomas or the 
ophthalmological features of NF2 (Ferner, 2007a). 
Multiple lipomas occur primarily on the trunk, proximal thighs and distal arms, and are 
inherited in an autosomal dominant fashion. Biopsy is sometimes necessary to differentiate 
cutaneous neurofibromas from schwannomas and lipomas (Ferner et al., 2007a). 
4. Diagnostic workup 
The diagnosis of NF 1 is mainly clinic and (Baser et al, 1996; Ferner, 2007b), as explained 
before, two of the major criteria based on the modified NIH criteria must be fulfilled. Given 
the variety of clinical symptoms and the fact that these are age-dependent, it is sometimes 
difficult to make the diagnosis of NF1 at an early age because children might have, for 
example, the typical “café au lait” spots but only develop other features of the disease years 
later (Korf, 2011). Therefore, a complete physical and neurological exam together with a family 
history, ocular and cognitive (addressing learning skills) assessment and appreciation of bone 
deformities and cardiovascular alterations (with measurement of blood pressure) should be 
performed when a hypothesis of NF1 is considered or in an at-risk descendent.  
Brain MRI is considered important at an early age for the exclusion of optic pathway glioma 
but for some aspects as sedation, costs and parents anxiety must be beared in mind. Bones 
imaging to look for bone dysplasia must also be assessed whenever a pain complaint occurs 
(Korf, 2011). 
Because half the cases are familial, genetic counseling is very important in NF1 due to the 
high morbidity and mortality associated to this disease. Parents of affected children should 
know that a 50% risk of NF1 mutation transmitting is associated to each pregnancy 
(Tonsgard, 2006). Attention should be paid to the possibility of the subject being a mosaic, 
because a simple blood sample may miss the affected cells. A tissue sample from a tumour 
must be ideally collected in these situations. 
For NF2 diagnosis the Manchester Criteria are the most commonly used. Therefore, as 
presented in Table 2, patients do not need to have a family history of NF2 or bilateral 
vestibular schwannomas but may have multiple other related lesions. Peripheral 
neuropathy and the presence of a constitutional NF2 mutation are not yet included in the 
diagnostic criteria of NF2 (Asthagiri et al, 2009; Baser et al., 1996; Gareth & Evans, 2009). 
Genetic testing could aid to rule out mutations in individuals from families with NF2 
avoiding additional exams (Baser et al., 1996; Gareth & Evans, 2009). 
The diagnostic evaluation as well, should always incorporate a thorough clinical and family 
history, a physical (including cutaneous), neurologic and as in NF1, ophthalmologic 
examination and a brain and spinal MRI with and without gadolinium (Gareth et al, 2009). 
MRI is the ideal imaging method when vestibular schwannomas are suspected but also to 
explore the presence of other cranial nerve tumours or meningiomas (Gutmann et al., 1997). 
The median age of NF2 diagnosis is 20-30 years with hearing loss as initial symptom. 
However, the clinical manifestations are age dependent and about 30% of children begin 
with other symptoms (Asthagiri et al, 2009; Gareth & Evans, 2009). 
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The screening of children with NF2 suspicion from an affected parent should include 
ophthalmologic examination (in the first ten years of life), neurologic examination 
(annually), audiology with auditory brainstem evoked potentials yearly from infancy 
(annually) and presymptomatic genetic testing (not before 10 years of age) (Evan et al., 1995; 
Gareth & Evans, 2009). MRI screening should be performed every 2 years when younger 
than 20 years of age and every 3 to 5 years when older than 20 years of age. However, if 
tumours are present screening should be done annually. For spinal MRI, the frequency 
should be every 3 years (Baser et al, 1996; Gareth & Evans, 2009). 
5. Molecular genetic diagnosis of neurofibromatosis 
5.1 Neurofibromatosis type 1 
NF1 is an autosomal dominant genetic disorder. The gene locus discovered by linkage 
analysis and subsequently positional cloning in 1990, is found on chromosome 17 (Barker et 
al., 1987; Viskochil et al 1990; Wallace et al, 1990). It is a large gene that spans greater than 
350-kb of genomic DNA, and it is composed of 60 individual exons (Gutmann et al 1999). 
The gene locus has a spontaneous mutation rate that is 100 times greater than average, and 
approximately half of NF1 cases appear to represent new mutations (Lewis and Riccardi 
1981). The reason for the unusually high mutation rate and the mechanism of mutation are 
unknown. However, the vast majority of new mutations occur on the paternally derived 
chromosome. This phenomenon does not appear to be linked to paternal age as in other 
genetic diseases (Jadayel et al., 1990), and it is known as “genomic imprinting” (Hall, 1990). 
The mechanism by which genomic imprinting may play a role in the spontaneous mutation 
rate, may involve hypermethylation of the sperm genome, which is then at higher risk for 
mutations through the spontaneous deamination of 5-methylcytosine (Rodenhiser et al., 
1993). 
The most common gene product is a polypeptide of 2,818 amino acids, called neurofibromin 
(Gutmann & Collins 1992; Danglot et al 1995; Li et al., 2002). Neurofibromin is expressed in 
neurons, oligodendrocytes, Schwann cells, the adrenal medulla and white blood cells 
(Daston et al 1992; Gutmann, 1998). Sequence analysis of the full length NF1 gene cDNA 
revealed a portion that codes for a 360 amino acid peptide with structural and functional 
similarities to some guanosine triphosphatase activating proteins (GAP) in other 
mammalian and yeast cells (Xu et al 1995). The portion of the gene that codes for this protein 
interacts with the protooncogene, p21ras (Martin et al., 1990; Shen et al., 1996). The 
abovementioned proteins have the ability to accelerate hydrolysis of ras-guanosine 
triphosphate to ras-guanosine diphosphate, thus, activating the proto-oncogene. In some 
sporadic tumors of non-NF1 patients, ras activating mutations are implicated in malignant 
transformation (Reed & Gutmann 2001). This was the first hypothesis to the possible 
function of neurofibromin (Gutmann & Collins 1992). Loss of neurofibromin activity 
through mutation could lead to cellular proliferation, and thus to some of the disease 
expression of NF1. The NF1 gene is thus considered a tumor-suppressor gene as loss-of-
function mutations have been associated with benign and malignant tumors in neural-crest-
derived tissues in patients with NF1 (Coleman et al 1995; Serra et al 1997), being 
neurofibromin a tumor suppressor by down-regulating or inhibiting intracellular ras 
activity (Gutmann and Collins 1992). But beyond ras regulation, important intracellular 
signaling pathways are probably regulated by neurofibromin as cAMP generation that 
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modulates cell growth and differentiation in the brain (Tong et al 2002). On the other hand, 
neurofibromin is highly expressed in Schwann cells, and may play a critical role in the 
formation of neurofibromas (Rutkowski et al., 2000).  
There may be basic differences in how NF1 gene expression influences the development of 
tumors or the cognitive manifestations. Some tumors occur when both copies of the gene are 
functionally inactivated or defects in growth regulation are caused by reduced protein 
expression. 
Some of the non-tumor features, including cognitive and learning problems, may be related 
to microenvironmental interactions between haploinsufficient astrocytes and neurons 
(Gutmann et al., 1999). 
Finally, neurofibromin has been shown to play a crucial role on modulating mesenchimal 
stem and progenitor cell differentiation into osteoblasts, and this effect may contribute to the 
osseous abnormalities seen in NF1 (Wu et al 2006)  
The factors that determine the genotype/phenotype correlations are not well understood 
(Ainsworth et al., 1993; Shen et al., 1996), and the discordance for several defining features 
of NF1 among pairs of monozygotic twins suggest that some manifestations are not entirely 
genetically controlled (Huson, 1994). 
Cloning of the NF1 gene brought hope for routine prenatal diagnosis, but the large size of 
the gene and large number of potential mutations make this unlikely for at least several 
years (Marchuk & Collins 1994). 
Genetic diagnosis is sometimes possible in NF1 families with two or more affected 
individuals by linkage analyses. Available polymorphic DNA markers, however, do not 
always have sensitivity enough to achieve it in all families (Marchuk & Collins, 1994). 
Conventional approaches to the identification of disease-causing mutations in individuals 
with NF1 have been limited because of the large size of the gene and the wide diversity of 
mutations, no clustering in any one region of the gene (Gutmann et al., 1999). For these 
reasons, identification of a mutation in a suspect case requires a variety of techniques to 
thoroughly examine DNA for mutations, most of them point mutations or small lesions 
leading to premature termination codons (Upadhyaya & Cooper, 1998). Some tests as the 
protein truncation test (in-vitro transcription-translation of the whole NF1 coding 
sequence (Heim et al., 1995) have been used to identify mutations, but it seems that a 
combination of approaches will be necessary (Gutmann et al., 1999). In addition, even 
when a mutation is identified, an individual risk is confirmed, but not how severely he 
will be affected. This point limits the usefulness of currently available technology for 
prenatal test.  
5.2 Neurofibromatosis type 2 
NF2 is now well characterized as an autosomal dominant inherited disease caused by 
mutation of a gene located on the long arm of chromosome 22(q11-13.1), distinct from NF1 
(Rouleau et al., 1987; Wertelecki et al., 1988).  
The abnormal gene product for NF2, merlin or Schawannomin identified in 1993 (Rouleau et 
al., 1993; Trofatter et al., 1993), functions as a tumor suppressor gene (Rouleau 1994). Unlike 
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protooncogenes, which cause tumors by producing a protein that stimulates cellular 
proliferation and requires only one abnormal copy of the gene to produce the abnormal 
gene product, a tumor suppressor gene requires a critical mutation of both copies (alleles) of 
the gene for the normal suppressor gene product to be absent or inactive. As with other 
tumor suppressor genes, the germ-line mutation produces 1 abnormal allele in all the cells 
of an affected individual, and presumably, a “second hit” of the other allele occurs later, in 
the tissue from which a tumor arises (Knudson 1985). Indeed, evidence for somatic 
inactivation of both NF2 alleles is found in the majority of schwannomas and meningiomas 
thar arise in these patients (Hung et al., 2000; Lamszus et al., 2000). 
The protein product, merlin, has a high degree of homology with a family of cytoskeletal 
proteins (ERM proteins) that link the actin skeleton of the cell to cell adhesion membrane 
proteins important for cellular remodelling and growth regulation (Trofatter et al., 1993). 
These proteins function looks like essential for the formation of specialized subcellular 
structures as well for adhesion and migration activities (McClatchey et al., 1998). Schwann 
cell cultures isolated from schwannomas of NF2 patients with identified germ-line 
mutations have shown striking differences in morphology, cell-cell contacts, and growth 
compared to normal control Schwann cells (Rosenbaum et al 1998). These findings permit to 
theorize that disruption of cytoskeletal organization by alteration in NF2 gene and protein 
product is involved in the genesis of tumors. Another approach to determine merlin 
functions, has involved molecules that interact with it and potentially transduce its growth 
suppressive signal. Merlin, like the ERM proteins, has an amino-terminal cell surface 
glycoprotein-binding domain (called FERM domain) with 3 subdomains that may mediate 
specific interactions with critical protein binding partners (Kang et al 2002; Shimizu et al 
2002). Several candidate proteins include: CD44 (Herrlich et al., 2000; Morrison et al., 2001), 
actin (Xu & Gutmann, 1998), beta II-spectrin (Scoles et al., 1996), SCHIP-1 (Goutebroze et al., 
2000), HRS (Scoles et al., 2000), NHE-RF (Gonzalez-Agosti et al., 1999) and beta1-integrin 
(Obremski et al., 1998). The merlin-actin association is tightly regulated by protein 
phosphorylation (Morrison et al 2001; Kissil et al 2002), and it is important for localizing 
merlin to the proper subcellular location (Fernandez-Valle et al., 2002). The association of 
merlin with CD 44 raises the possibility that merlin could function as a molecular switch. 
The merlin’s ability to associate with CD44 may be influenced by merlin’s phosphorylation 
state, intramolecular complex formation, and its interactions with other binding partners. 
With these influences, merlin may determine whether it traduces a growth stimulatory or 
inhibitory signal (Pearson et al 2000). Merlin also associates with other Schwann cell growth 
regulators. Hepatocyte growth factor-regulated tyrosine kinase substrate binds through 
residues in the C-terminal domain not shared with ERM proteins (Scoles et al 2000). This 
factor is one of the most potent stimuli for Schwann cell proliferation and motility 
(Gutmann et al 2001). 
Approximately half of the cases of NF2 appear to be the result from a new gene mutation 
(Evans et al., 1992a) although the mutation rate is lower than of NF1. The mechanism of 
mutation is currently unknown, but has been shown to be related to increased paternal age 
(Evans et al., 1992a). Further analysis has shown a clearer link between the risk of mosaicism 
inheritance by offspring and age of vestibular schwannoma diagnosis (Evans & Wallace, 
2009). Patients who inherit NF2 from their mothers generally have an earlier age of 
presentation and a more rapidly progressive course (Eldridge, 1990; Evans et al., 1992a). 
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This suggests the possibility of gene modification by a mechanism of maternal imprinting 
(Hall, 1990). On the other hand, different NF2 mutations result in varying disease courses. 
Point mutations are found in about 55% of cases clinically diagnosed, and genotype-
phenotype correlations have been established based on the relationship between NF2 
mutations and clinical severity (Parry et al., 1996; Evans et al., 1998a) Patients with 
constitutional mutations that produce a truncated protein with loss of merlin expression 
(generally nonsense or frameshift mutations) have an earlier onset, number and rate of 
growth of CNS tumors (Selvanathan et al 2010). Missense, in-frame mutations or large 
deletions result in the generation of merlin proteins defective in their negative growth 
regulatory ability (Gutmann et al., 1998b), with milder disease (Parry et al., 1996; Evans et 
al., 1998). However, exception to these correlations have been reported (Scoles et al 1996), 
suggesting that other factors different to the class of mutation are likely to be responsible for 
a portion of the clinical symptoms (Welling 1998). 
Currently, linkage analysis using tightly-linked genetic markers has been available to 
determine NF2 mutations carrier status in at-risk individuals in families with this disease 
from at least two generations. The relatively low detection rate of mutations (55%) may be 
partially related to somatic mosaicism in sporadic cases (Bijlsma et al., 1997; Evans et al., 
1998; Kluwe et al., 1998), as well as a significant number of gene deletions observed. 
The child of a parent with NF2 has a 50% risk of having the disease (Evans et al 1992a), and 
even no mutation was detected due to the common gonosomal mosaicism found, 
penetrance is thought to be complete, with initial symptoms until age 35 to 60 (Evans et al 
1992b; Eldridge 1990). Newer techniques for detection of protein truncations have been 
developed, but they are not still validated for NF2 patients without bilateral vestibular 
schwannomas, and its ability to detect mosaic mutations remains untested (Gutmann et al, 
1998b). Since RNA mismatch cleavage method is available, tumors mutations are detected 
with higher sensitivity, so this technique could be used as a convenient method for germline 
NF2 mutations screening (Faudoa et al 2000; Hung et al 2000)  
These and possibly other streamlined methods may eventually make the genetic diagnosis 
of NF2 in suspected cases, including sporadic ones in the future (Bourn et al 1994; Rouleau, 
1994; Merel et al 1995; Legoix et al 1999). At present, in most families with more than one 
affected individual, linkage analysis still remains the test of choice, as this will provide a 
greater than 99% certainty of NF2 diagnosis. 
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